Neramexane mesylate

DRUG7 trials

Sponsors

Merz Pharmaceuticals GmbH

Conditions

HealthyMultiple SclerosisNystagmus, AcquiredNystagmus, CongenitalNystagmus, Congenital IdiopathicSubjective Tinnitus

Phase 1

Investigate the Effect of Neramexane Mesylate IR Tablet on Driving Fitness and Capability to Operate Machines in Healthy Volunteers

CompletedNCT00712283

Merz Pharmaceuticals GmbHHealthy

Start: 2008-07-31End: 2009-06-30Target: 64Updated: 2009-12-07

Phase 2

Efficacy and Safety Study of Neramexane to Treat Congenital and Acquired Nystagmus

CompletedNCT00661440

Merz Pharmaceuticals GmbHNystagmus, Acquired, Nystagmus, Congenital Idiopathic

Start: 2008-05-31Target: 48Updated: 2009-11-26

Open-lable Extension Study on Safety and Efficacy of Neramexane to Treat Congenital and Acquired Nystagmus

TerminatedNCT00799942

Merz Pharmaceuticals GmbHMultiple Sclerosis, Nystagmus, Acquired, Nystagmus, Congenital

Start: 2009-05-31Target: 48Updated: 2010-07-01

Phase 3

Efficacy, Safety and Tolerability of Neramexane in Patients With Subjective Tinnitus

CompletedNCT00739635

Merz Pharmaceuticals GmbHSubjective Tinnitus

Start: 2008-09-30End: 2010-02-28Updated: 2016-02-04

Efficacy, Safety and Tolerability of Neramexane in Comparison to Placebo in Patients With Subjective Tinnitus

CompletedNCT00772980

Merz Pharmaceuticals GmbHSubjective Tinnitus

Start: 2008-11-30End: 2010-06-30Target: 400Updated: 2010-07-01

Open-Label, Long-Term Treatment Study, to Assess the Long-Term Safety and Tolerability and Efficacy of Neramexane in Patients With Subjective Tinnitus

TerminatedNCT00827008

Merz Pharmaceuticals GmbHSubjective Tinnitus

Start: 2009-01-31End: 2011-12-31Updated: 2012-11-28

Efficacy, Safety, Tolerability of Neramexane in Patients With Subjective Tinnitus

CompletedNCT00955799

Merz Pharmaceuticals GmbHSubjective Tinnitus

Start: 2009-09-30End: 2011-06-30Updated: 2012-11-28